Return on Equity (ROE)
Updated 54h ago
Sector Performance
56th percentileFCX
15.6%
Sector Median
13.8%
Sector Avg
31.4%
Deep Analysis
Return on Equity (ROE) measures how efficiently a company generates profit from its shareholders' money — at 15.6%, FCX earns roughly $0.156 for every dollar of equity.
This sits above the sector median of 13.8% and places the company at the 55th percentile among its peers, meaning it outperforms just over half of them. The year-over-year change and quarter-over-quarter change are both listed as N/A, so there is no available trend data to assess direction over the last eight quarters. Because the ROE level is above the sector median but the trend is unknown, the risk or opportunity cannot be inferred from momentum alone — the single data point offers only a snapshot. This metric supports the overall CAUTIOUS verdict: the ROE is moderately above average, but without trend confirmation, it does not provide enough positive evidence to override a cautious stance.
Frequently Asked Questions
What does the Return on Equity (ROE) tell investors about FCX?
ROE measures how effectively management turns equity into profit. Consistently above 15% is typically considered strong. Negative equity distorts this metric.
How is the Return on Equity (ROE) calculated?
Return on Equity (ROE) is calculated as: Net Income / Shareholders' Equity.
Who are FCX's closest peers by Return on Equity (ROE)?
The closest peers by Return on Equity (ROE) include: MRNA (-36.6%), FICO (-37.3%), XRAY (-37.7%), VRSN (-38.3%), MSCI (-45.3%).
The Formula
Net Income / Shareholders' Equity
Why It Matters
ROE measures how effectively management turns equity into profit. Consistently above 15% is typically considered strong. Negative equity distorts this metric.
Master FCX's Valuation
Get the complete institutional research report covering all fundamental and technical metrics.
View full FCX research report →FCX
15.6%
Sector Median
13.8%
Sector Avg
31.4%
How FCX's Return on Equity (ROE) compares to sector peers.
Also Analyze
Not financial advice. Research tool only. Data may be delayed.